Functional level and quality of life in ankylosing spondylitis, pilot study after 16 weeks TNF blocker treatment;Nivel funcional y calidad de vida en espondilitis anquilosante. Estudio piloto tras 16 semanas de tratamiento anti-TNF

Revista Espanola de Geriatria y Gerontologia

Volumn 45, Issue 6, 2010, Pages 331-334

  Abalos Medina, Gracia María ^a   Ruiz Villaverde, Gonzalo ^b   Sánchez Cano, Daniel ^a   Ruiz Villaverde, Ricardo ^c   Ocaña Peinado, Francisco ^d   Villaverde Gutiérrez, Carmen ^d  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c Servicio de Dermatología   (Spain)

^d UNIVERSITY OF GRANADA   (Spain)

Author keywords

Ankylosing spondylitis; Quality of life; TNF blocker therapy

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; FUNCTIONAL DISEASE; HEALTH SERVICE; HOSPITAL; HUMAN; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RHEUMATOLOGY; TREATMENT DURATION; VISUAL ANALOG SCALE;

EID: 78649858929     PISSN: 0211139X     EISSN: 15781747     Source Type: Journal    
DOI: 10.1016/j.regg.2010.04.010     Document Type: Article

References (13)

1. Sanmartí R., Cañete J.D. Espondilitis Anquilosante. Tratado de Reumatología 1998, 997-1019. Aran Ediciones, Madrid. E. Pascual, V. Rodriguez-Valverde, J. Carbonell, J.J. Gomez Reino (Eds.).
2. Calin A., Garrett S., Whitelock H., Kennedy L.G., O'Hea J., Mallorie P., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
3. Collantes-Estevez E., Muñoz-Villanueva M.C., Cañete-Crespillo J.D., Sanmarti-Sala R., Gratacós-Masmitjá J., Zarco-Montejo P., et al. Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. Ann Rheum Dis 2003, 62:1239-1240.
4. Freeston J., Barkham N., Hensor E., Emery P., Fraser A. Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies. Joint Bone Spine 2007, 74:140-143.
5. Ariza-Ariza R., Hernández-Cruz B., Navarro-Sarabia F. Physical function and health related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 2003, 49:483-487.
6. Garrett S., Jenkinson T., Kennedy L.G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
7. Ariza-Ariza R., Hernández-Cruz B., Navarro-Sarabia F. La versión española del BASDAI es fiable y se correlaciona con la actividad de la enfermedad en pacientes con espondilitis anquilosante. Rev Esp Reumatol 2004, 31:372-378.
8. Braun J., Pham T., Sieper J., Landewe R.B., Van der Linden S., Dougados M., et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003, 62:817-824.
9. Collantes E., Fernández Sueiro J.L., García-Vicuña R., Gratacós J., Mulero J., Muñoz Fernández S., et al. Actualización del consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNF-alfa en las espondiloartritis, incluida la artritis psoriásica. Reumatol Clin 2007, 3(Supl 2):S61-S71.
10. Cardiel M.H., Londono J.D., Gutierrez E., Pacheco-Tena C., Vazquez-Mellado J. Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol 2003, 21:451-458.
11. Doward L.C., Spoorenberg A., Cook S.A., Whalley D., Helliwell P.S., Kay L.S., et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003, 62:20-26.
12. Han C., Smolen J., Kavanaugh A., Van der Heijde D., Braun J., Westhovens R., et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007, 9:R103.
13. Boonen A., Patel V., Traina S., Chiou C.-F., Maetzel A., Tsuji W. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 2008, 35:662-667.